Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Edgewise Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 201
- +25 vs. Q3 2024
- Shares held
- 99.0M
- −2.18M (−2.2%) vs. Q3 2024
- Total value
- $2.64B
- −$58.2M (−2.2%) vs. Q3 2024
- New holders
- 45
- 71 more added
- Sold out
- 20
- 63 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EWTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 226 | $4.82B |
| Q1 2026 | 214 | $3.72B |
| Q4 2025 | 199 | $3.02B |
| Q3 2025 | 173 | $1.82B |
| Q2 2025 | 179 | $1.56B |
| Q1 2025 | 193 | $2.32B |
| Q4 2024 | 201 | $2.64B |
| Q3 2024 | 177 | $2.71B |
| Q2 2024 | 140 | $1.83B |
| Q1 2024 | 129 | $1.67B |
| Q4 2023 | 116 | $871.4M |
| Q3 2023 | 85 | $392.2M |
| Q2 2023 | 95 | $538.8M |
| Q1 2023 | 85 | $443.1M |
| Q4 2022 | 90 | $594.1M |
| Q3 2022 | 94 | $633.5M |
| Q2 2022 | 78 | $405.7M |
| Q1 2022 | 72 | $523.5M |
| Q4 2021 | 58 | $769.4M |
| Q3 2021 | 48 | $795.8M |
| Q2 2021 | 46 | $1.03B |
| Q1 2021 | 31 | $1.48B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Edgewise Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 15,021,721 | $401.1M | 8.33% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −2,112,984−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −1,250,385−100.0% | Sold out |
| VR Adviser, LLC | 0 | $0 | 0.00% | −1,000,000−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −75,000−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −45,400−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −39,937−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −29,629−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −28,303−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −27,465−100.0% | Sold out |
| NEOS Investment Management LLC | 0 | $0 | 0.00% | −23,359−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −21,128−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −20,551−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| ADAR1 Capital Management, LLC | 0 | $0 | 0.00% | −18,178−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −13,335−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Chicago Partners Investment Group LLC | 0 | $0 | 0.00% | −6,018−100.0% | Sold out |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −7,686−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −1,200−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Ghost Tree Capital, LLC | – | – | – | – | Not filed |